Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.48 |
| ▸ | HTR7 | P34969 | 4/20 | 0.48 |
| ▸ | DRD2 | P14416 | 8/20 | 0.48 |
| ▸ | DRD4 | P21917 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL210345 | 0.85 | HTR2A (0.53) | HTR2AHTR7DRD2DRD4SIGMAR1 | |
| SCHEMBL2734696 | 0.84 | DRD2 (0.49) | HTR2AHTR7DRD2DRD4SIGMAR1 | |
| SCHEMBL2734085 | 0.84 | DRD2 (0.53) | HTR2AHTR7DRD2DRD4SIGMAR1 | |
| SCHEMBL2734694 | 0.79 | HTR2A (0.51) | HTR2AHTR7DRD2DRD4SIGMAR1 | |
| SCHEMBL13453339 | 0.77 | HTR2A (0.49) | HTR2AHTR7DRD2DRD4SIGMAR1 | |
| SCHEMBL2734082 | 0.76 | HTR2A (0.57) | HTR2AHTR7DRD2DRD4SIGMAR1 | |
| SCHEMBL2734240 | 0.72 | HTR2C (0.53) | HTR2ADRD2 | |
| SCHEMBL2733202 | 0.72 | HTR2C (0.51) | HTR2AHTR7DRD2HTR6 | |
| SCHEMBL2734416 | 0.72 | DRD2 (0.64) | HTR2AHTR7DRD2DRD4SIGMAR1 | |
| SCHEMBL2733199 | 0.70 | HTR2A (0.55) | HTR2AHTR7DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | GABRA5, HCRTR2, HCRTR1 | HTR2A 128/4885HTR7 60/4885DRD2 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.